Advanced search
1 file | 536.36 KB Add to list

Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT

Author
Organization
Abstract
Objective The primary objective of this study was to assess clinical outcomes in patients with oligometastatic prostate cancer recurrence after single or repeated salvage radiation treatment. Methods Forty-nine consecutive prostate cancer patients diagnosed with oligometastatic recurrence on Ch-PET have been prospectively treated. Seven (23%) patients had castrate-resistant disease. Clinical outcomes were assessed using the Kaplan-Meier method. Potential prognostic factors were examined using univariate proportional hazards regression. Results The treatments administered to the initial oligorecurrence sites were intensity-modulated radiotherapy (IMRT) +/- ADT (26 patients; 53%) and stereotactic ablative radiotherapy (SABR) +/- ADT (23 patients; 47%). With a median follow-up of 24 months (range 6-39), 24 patients developed a biochemical failure. Twenty out of the 24 relapsed patients underwent a second Ch-PET/CT. Seven patients presented poly-metastatic relapse and 10 oligometastatic diseases. Six of 10 patients with a second oligorecurrence were treated again with SABR. Overall, 102 lesions were treated. Local control was detected in 45 (91.8%) patients. No relevant (grade >= 2) toxicity was reported, and there was no grade 3 toxicity. On univariate analysis, none of the variables were significantly predicted for clinical disease-free survival. At last follow-up visit, 24 patients (40%) were free from biochemical failure and 37 (71%) patients were free from clinical disease. The 2-year OS and PCSS were 91.8% and 95.9% respectively. Conclusion Salvage IMRT or SBRT of oligometastatic prostate cancer recurrence is associated with a prolonged cDFS. This may result in a longer time to develop castrate-resistant disease and a longer time without systemic therapies.
Keywords
POSITRON-EMISSION-TOMOGRAPHY, BODY RADIATION-THERAPY, METASTASIS-DIRECTED THERAPY, CHEMOHORMONAL THERAPY, RADIOTHERAPY, SURVIVAL, FAILURE, LEVEL, MEN, choline PET, oligometastases, oligorecurrence, radiotherapy, SABR

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 536.36 KB

Citation

Please use this url to cite or link to this publication:

MLA
Gomez-Iturriaga, Alfonso, et al. “Outcomes after a First and/or Second Salvage Treatment in Patients with Oligometastatic Prostate Cancer Recurrence Detected by (18-F) Choline PET-CT.” EUROPEAN JOURNAL OF CANCER CARE, vol. 28, no. 5, 2019, doi:10.1111/ecc.13093.
APA
Gomez-Iturriaga, A., Casquero Ocio, F., Ost, P., Fernandez, I., Rodeno, E., Llarena, R., … Bilbao, P. (2019). Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT. EUROPEAN JOURNAL OF CANCER CARE, 28(5). https://doi.org/10.1111/ecc.13093
Chicago author-date
Gomez-Iturriaga, Alfonso, Francisco Casquero Ocio, Piet Ost, Iratxe Fernandez, Emilia Rodeno, Roberto Llarena, Jorge Garcia-Olaverri, et al. 2019. “Outcomes after a First and/or Second Salvage Treatment in Patients with Oligometastatic Prostate Cancer Recurrence Detected by (18-F) Choline PET-CT.” EUROPEAN JOURNAL OF CANCER CARE 28 (5). https://doi.org/10.1111/ecc.13093.
Chicago author-date (all authors)
Gomez-Iturriaga, Alfonso, Francisco Casquero Ocio, Piet Ost, Iratxe Fernandez, Emilia Rodeno, Roberto Llarena, Jorge Garcia-Olaverri, Roberto Ortiz de Zarate, Jon Cacicedo, Alina Ahtamon, and Pedro Bilbao. 2019. “Outcomes after a First and/or Second Salvage Treatment in Patients with Oligometastatic Prostate Cancer Recurrence Detected by (18-F) Choline PET-CT.” EUROPEAN JOURNAL OF CANCER CARE 28 (5). doi:10.1111/ecc.13093.
Vancouver
1.
Gomez-Iturriaga A, Casquero Ocio F, Ost P, Fernandez I, Rodeno E, Llarena R, et al. Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT. EUROPEAN JOURNAL OF CANCER CARE. 2019;28(5).
IEEE
[1]
A. Gomez-Iturriaga et al., “Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT,” EUROPEAN JOURNAL OF CANCER CARE, vol. 28, no. 5, 2019.
@article{8674295,
  abstract     = {Objective The primary objective of this study was to assess clinical outcomes in patients with oligometastatic prostate cancer recurrence after single or repeated salvage radiation treatment. Methods Forty-nine consecutive prostate cancer patients diagnosed with oligometastatic recurrence on Ch-PET have been prospectively treated. Seven (23%) patients had castrate-resistant disease. Clinical outcomes were assessed using the Kaplan-Meier method. Potential prognostic factors were examined using univariate proportional hazards regression. Results The treatments administered to the initial oligorecurrence sites were intensity-modulated radiotherapy (IMRT) +/- ADT (26 patients; 53%) and stereotactic ablative radiotherapy (SABR) +/- ADT (23 patients; 47%). With a median follow-up of 24 months (range 6-39), 24 patients developed a biochemical failure. Twenty out of the 24 relapsed patients underwent a second Ch-PET/CT. Seven patients presented poly-metastatic relapse and 10 oligometastatic diseases. Six of 10 patients with a second oligorecurrence were treated again with SABR. Overall, 102 lesions were treated. Local control was detected in 45 (91.8%) patients. No relevant (grade >= 2) toxicity was reported, and there was no grade 3 toxicity. On univariate analysis, none of the variables were significantly predicted for clinical disease-free survival. At last follow-up visit, 24 patients (40%) were free from biochemical failure and 37 (71%) patients were free from clinical disease. The 2-year OS and PCSS were 91.8% and 95.9% respectively. Conclusion Salvage IMRT or SBRT of oligometastatic prostate cancer recurrence is associated with a prolonged cDFS. This may result in a longer time to develop castrate-resistant disease and a longer time without systemic therapies.},
  articleno    = {e13093},
  author       = {Gomez-Iturriaga, Alfonso and Casquero Ocio, Francisco and Ost, Piet and Fernandez, Iratxe and Rodeno, Emilia and Llarena, Roberto and Garcia-Olaverri, Jorge and Ortiz de Zarate, Roberto and Cacicedo, Jon and Ahtamon, Alina and Bilbao, Pedro},
  issn         = {0961-5423},
  journal      = {EUROPEAN JOURNAL OF CANCER CARE},
  keywords     = {POSITRON-EMISSION-TOMOGRAPHY,BODY RADIATION-THERAPY,METASTASIS-DIRECTED THERAPY,CHEMOHORMONAL THERAPY,RADIOTHERAPY,SURVIVAL,FAILURE,LEVEL,MEN,choline PET,oligometastases,oligorecurrence,radiotherapy,SABR},
  language     = {eng},
  number       = {5},
  pages        = {7},
  title        = {Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT},
  url          = {http://dx.doi.org/10.1111/ecc.13093},
  volume       = {28},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: